Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Merck has had a successful track record of beating estimates, having surpassed EPS expectations 88% of the time and beating ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord ...

Global life reinsurance provider Reinsurance Group of America (NYSE:RGA) will be reporting earnings this Thursday after ...

Regeneron Pharmaceuticals is on the cusp of unveiling its Q2 2025 earnings this Friday, with expectations pinned at $8.53 per share and a revenue forecast of $3.30 billion. Analysts are eyeing a ...

Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387 ...

John G Ullman & Associates Inc. made a hefty bet on Regeneron Pharmaceuticals, upping their stake by a whopping 94%, now ...

What To Expect From Tesla After Musk Returned From D.O.G.E. Here's a closer look at what the Street is expecting.

Molina cuts 2025 earnings outlook again on ACA, Medicaid pressures The California-based insurer outlined its plans to survive what CEO Joe Zubretsky deemed a “season of great uncertainty.” ...